Antiviral medicine

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a 1% ointment containing fullerene-polyhydropolyaminocaproic acid as active substance and auxiliary substances of dimethylsulfoxide, water-free lanolin and Vaseline in the following amount (g): fullerene-polyhydropolyaminocaproic acid 1.0, diemthylsulfoxide 10.0, water-free lanolin 10.0, Vaseline up to 100.0.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

 

The invention relates to pharmaceutical industry and relates to the creation of tools for the treatment of viral diseases, including HIV infection (AIDS and HIV-associated diseases).

The complex specific drugs for the treatment of viral infections, consisting of interferon, which is administered rectally in the form of an aqueous solution, and vitamins E and C, which is administered in the form of oil solution intramuscularly in parallel with interferon (ed. mon. The USSR №1530189, 1988).

Small synthetic antiviral agents - Medinan, methisazone - find limited prophylactic use, such as iodoxuridine, oksolina are applied topically in viral diseases of the skin, and the toxicity of the first very high (Pharmacology, M, Medicine, 1981, s-401)

Known drugs have long latency period, which creates the risk of exposure of the organism to the development of the maximum protective effect of interferon, and, in addition, a known antiviral agents have a certain toxicity.

The present invention is the creation of facilities possessing antiviral activity, especially effective in the treatment of HIV infection.

To solve the problem proposed antiviral agent, executed in the form of a 1% ointment containing fullerene-floor is hydroalumination acid as the active substance and excipients dimethyl sulfoxide, anhydrous lanolin and vaseline in the following ingredients in grams:

fullerene-polyhydroxyalkanoate acid1,0
the sulfoxide10,0
lanolin anhydrous10,0
vaselineto 100.0

Fullerene-polyhydroxyalkanoate acid is a powder dark brown, almost black, color with no odor. The connection is not soluble either in water or chloroform, but soluble in dimethyl sulfoxide (100 mg/ml), so it is soluble in water and in chloroform.

Most chemical reactions with the fullerenes are not selective, which complicates the synthesis of individual compounds. Therefore, in the product are present as position isomers, and compounds that differ in the number of attached amino acids.

Derivative of fullerene and aminocaproic acid with the number of connected groups of at least 2 General formula:

C60Hn[NH(CH2)5C(O)O-]n,

where C60- fullerene core,

[NH(CH2)5C(O)O-] - aminocapronic anion

The ointment is prepared as follows.

A portion of the fullerene-polyhydroxyalkanoates is islote 1 g dissolved in 10 mg of dimethyl sulfoxide. 10 g of lanolin is melted at 40-60°C, then cooled to 40°lanolin and mix with a solution of fullerene-polyhydroxyalkanoic acid in DMSO for 30 min until a homogeneous mass in a water bath at a temperature of 35°With (not above 40°). Then in the resulting mass contribute vaseline to 100 g of the finished product, mix with the mixer until you obtain a uniformly colored mass.

Ready ointment dark brown color with gloss.

Ointment pack of 2 g aluminum tube primed, Bouchon, internal coating, the latex ring and membrane integrity. Bouchon is equipped with membranoproliferative.

Ointment store protected from light and out of reach of children, in a cool dry place for 2 years, an open tube of eye ointment should be used within 1 month.

The ointment is recommended for local and external use as antiviral agents (herpes viral infections: herpes simplex skin and mucous membranes in patients with immune system disorders, genital herpes (primary and recurrent), herpes zoster, chicken pox).

The drug is prescribed for herpes virus infections; in the affected areas of skin and mucous membranes using disposable chopsticks put ointment 5 times per day rate not less than 5 days before the disappearance of symptoms.

The tool was aprobarea is but in the Institute of Virology. Dijanoveckog Russian Academy of medical Sciences and clinical infectious diseases hospital No. 2 (Nizhny Novgorod).

Tests in vitro and clinical trials showed that the drug:

- highly active against herpes simplex virus (Herpes simplex) type I and II; the virus that causes chickenpox and shingles (Varricella zoster)virus, Epstein-Barr, cytomegalovirus;

- the use of the drug in the treatment of patients with herpes viral infections, low immune status leads to an increase in the duration of remission;

- the drug is able to prevent the formation of lesions when applied at the first symptoms of recurrent herpes simplex;

the drug helps to eliminate pain, reduce the number of lesions, accelerate their disappearance;

- the drug has immunostimulating effect.

In some cases, immediately after application of the ointment may be short-term feeling weak burning sensation. May cause local irritation of the mucous membranes, disappearing after drug withdrawal.

It is assumed that because the ointment does not penetrate into the cell, there is no danger of its interaction with other antiviral drugs.

Antiviral agent, characterized in that it is made in the form of a 1% ointment contains fullerene-polyhydroxyalkanoate acid as Akti the aqueous substances and excipients dimethyl sulfoxide, anhydrous lanolin and vaseline in the following ingredients:

fullerene-polyhydroxyalkanoate acid1,0
the sulfoxide10,0
lanolin anhydrous10,0
vaselineto 100.0.



 

Same patents:

Antiviral medicine // 2333751

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a suppository containing fullerene-polyhydropolyaminocaproic acid and auxiliary substances of dimethylsulfoxide, water-free lanolin or vegetable oil selected out of olive, peach, bumpkin seed oil, and base selected out of W-35 or H-15 vitepsol, cacao butter, solid fat, in the following amount per one 2 g suppository: fullerene-polyhydropolyaminocaproic acid 5-20 mg, diemthylsulfoxide 50-200 mg, water-free lanolin or vegetable oil 20-100 mg, the rest being the base.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

FIELD: chemistry.

SUBSTANCE: invention relates to the new isoflavon derivative of tectorigenine compound of formula (II) , where R1 represents H, NH2 or SO3M; R2 represents OR'; R3 represents H or -CH2NR"; wherein R' represents H, -CH2COONa or -CH2CH2NMe2; NR" represents or -NMe2; M represents H, Na, K or N+H(CH2CH2OH)3, it also relates to virus inactivating agent having this derivative as an active ingredient and to the method for preparation of the injections on its basis.

EFFECT: developing of production method for the injections on basis of tectorigenine.

20 cl, 10 tbl, 2 dwg,10 ex

FIELD: medicine; veterinary.

SUBSTANCE: medicine for bird influenza treatment includes activated-potentiated form of antibodies to bird alpha, beta and gamma interferon obtained by multiple sequential cultivation and external affection by homeopathic technology.

EFFECT: improved efficiency of treatment.

4 cl, 3 ex

FIELD: medicine; pediatrics.

SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.

EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.

7 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention claims application of starches substituted by quarterly ammonium groups with substitution degree of 0.4 to 3.0 with the help of a linker, in infection diseases treatment. Suppression of 1 type herpes virus replication by the claimed starches is demonstrated, in comparison to zero antivirus effect of non-modified starches. Minimal inhibiting concentration for staphylococci and mycobacteria is 5-60 g/l.

EFFECT: efficient infection disease treatment by the claimed starches.

5 cl, 7 tbl

FIELD: chemistry, pharmaceuticals.

SUBSTANCE: invention pertains to compounds with formula (I), their pharmaceutical salts or N-oxide used as an inhibitor to replication and/or proliferation of HCV, to the method of inhibiting replication or proliferation of hepatitis C virion using formula (I) compounds, as well as to pharmaceutical compositions based on them. The compounds can be used for treating or preventing infections, caused by hepatitis C virus. In general formula (I) cycle B is an aromatic or non-aromatic ring, which contains two heteroatoms, where X and Y, each is independently chosen from C, CH, N or O, under the condition that, both X and Y are not O and that, both X and Y are not N; U and T represent C; Z represents -CH-; A represents N or -CR2-; B represents -CR3-; D represents N or -CR4-; E represents N or -CR5-; G represents N or -CR6-; J represents N or -CR14-; K represents -CR8-; L represents N or -CR9-; M represents N or -CR10-; R2 and R6, each is independently chosen from a group, consisting of hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, C1-C6substituted alkoxy, C1-C6alkoxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, -O-carbamoil, substituted -O-carbamoil, halogen C1-C6alkyl, diC1-C6alkylamino, substituted diC1-C6alkylamino and sylye ethers, where cycloheteroalkyl is a 3-7-member ring, containing 1-2 heteroatoms, chosen from N and O, under the condition that, one of R2 and R6 is not hydrogen; R3 and R5, each is independently chosen from a group, consisting of hydrogen, halogen; R4 represents hydrogen; R7 represents - NR11C(O)R12; R8, R9, R10 and R14, each is independently represents hydrogen; R11 represents hydrogen, C1-C6alkyl; and R12 is chosen from a group, consisting of halogen C1-C6alkyl; where each substituted group is substituted with one or more groups, chosen from -Q, -R40, -OR40, -C(O)R40, -C(O)OR40, where each Q independently represents halogen, R40 and R41 are independently chosen from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, under the condition that: (i) at least one of A, D, E, G, J, L or M represents N; (ii) not more than one of A, D, E or G represents N; and (iii) not more than one of J, L or M represents N.

EFFECT: obtaining pyridyl-substituted heterocycles for treating and preventing infections, caused by hepatitis C virus.

33 cl, 85 dwg, 101 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.

EFFECT: development of effective method applied for treatment and prevention of bird influenza.

6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.

EFFECT: offered combination has synergetic action if taken in any molar ratios.

33 cl, 6 dwg, 9 tbl, 4 ex

FIELD: bioengineering.

SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.

EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.

13 cl, 5 dwg, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to creation and application of aerosol spray compositions for treatment of diseases or disorders requiring lowering of cell proliferation and/or induction of cell apoptosis, such as neoplastic, autoimmune, viral diseases. Agent contains as active substance vitamin E based composition of structural formula , where R1 is carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkyl; or where R1 is hydrogen or carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkenyl.

EFFECT: improved delivery of specified composition by inhalation with intensified antiproliferation activity.

59 cl, 17 dwg, 6 tbl, 35 ex

FIELD: medicine.

SUBSTANCE: invention relates to topical formulation with: spironolactone nanoparticles, containing medium-diameter nanoparticles measured by photonic correlation spectroscopy technique, in the range approximately 300 nm to 900 nm, and dispersion of solid polar lipids crystals in polar liquid, with additional stabiliser. The nanoparticles are included in crystal structure formed by solid polar lipids crystals; the lipids mentioned being directed their hydrophilic ends outside, and hydrophobic ends inside, relative to spironolactone nanoparticles. Items of the patent application are also as follows: method of producing the formulation, the crystal lattice arrangement of solid polar lipids crystals with spironolactone nanoparticles included, and use of the nanosuspension with structure mentioned for medication producing, intended for therapy in anti-androgen responding conditions.

EFFECT: achieving of high stability formulation and increased bioavailability of spironolactone.

17 cl, 4 ex, 8 tbl, 11 dwg

Ophthalmic ointment // 2331408

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine, particularly ophthalmology, and can be applied to treatment for dystrophy or traumatic erosion of cornea, various keratitis, and chemical burns of conjunctiva and cornea. The ophthalmic ointment includes aecol as active substance, and ingredients in certain ratio: methylcellulose, polyvinyl pyrrolidone, nipagin, and nipazole, as ointment base.

EFFECT: increase in therapeutic efficacy of eye ointment, and reduction of treatment period for eye traumatic injury.

1 tbl, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to new composition of antifungal and fungicidal action, and applied for treatment of diseases caused by bacterial and fungal infection. Composition of prolonged action contains active substances antibacterial (chlorhexidine 0.02-0.05 mass%), antifungal (clotrimasole - 0.4-0.6 mass%), dimexide (7.0-27.0 mass%) as potentiator intensifying penetration of active substances, and also the stabiliser based on polyvinyl alcohol solution in physiologic saline, and structurally represents polymeric matrix with immobilised active components made as gel or a film from which active components are gradually released during application.

EFFECT: invention provides reduction of treatments time for ENT-diseases and dermal diseases of both candidal and mixed aetiology.

3 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to urology and concerns prevention of urethra iatrogenic infection caused by transurethral manipulations. For this purpose 5 minutes prior to urinary tracts manipulation gel is introduced to urethra that contains 2 g of 10 % lydocaine solution per 100 g of glycerine. Before introduction gel is ozonised to ozone concentration 1200 mkg/l. Method provides effective prevention of urethra iatrogenic infection at absence of lydocaine by-effects.

EFFECT: provided effective prevention of urethra iatrogenic infection at absence of lydocaine by-effects.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: ointment includes vegetable raw materials: sprouts and buds of poplar, aspen or willow, swallowwort (herb and blossom), common wormwood herb, yellow melilot (herb and blossom), costmary (herb and blossom), silver fir (sprouts), Siberian cedar (sprouts), pine resin and fat base, vegetable raw materials ratio is 1:10. As fat base composition contains unsalted pork fat.

EFFECT: extended range of preventive and therapeutic vegetable-based medicinal agents providing effective treatment of inflammatory diseases.

2 cl, 3 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical formulation for local application contain ketoprofen, solysobenzone in amount 2-4 mass.%, butylhydroxianisole in amount 0.05 to 0.2 mass.%, if required combined with pharmaceutically acceptable excipient. Composition protects ketoprofen from destruction caused by ultraviolet A, and is applied for treatment of inflammatory pathologies and musculoskeletal diseases.

EFFECT: no phototoxicity and photoallergenicity; increased permeability and rapid analgesic effect.

13 cl, 8 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: dermatologic stick is shard and contains corticosteroid, as well as petrolatum, paraffin, propylene glycol and emulsifier. Components are taken in effective amounts. Hard stick is enclosed in protective cover so that while applied it is not contacting with hand. Stick is not spread and flow about the skin and stays within application zone.

EFFECT: provided method of skin application for skin diseases treatment.

25 cl, 1 ex, 4 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: invention concerns medicinal agent applied for various dermal diseases, injuries, stab, cut and septic wounds, burns and frostbites. Stated medicinal agent is antiseptic ointment containing iodophor as reactant, and polyethylene glycol as ointment base. As iodophor stated ointment contains pharmaiodine, and as ointment base - mixed polyethylene oxide-1500, polyethylene oxide-400 and glycerine taken in proportions as follows, (mass.%): pharmaiodine 5.0-20.0 (0.5-2.0 by active iodine); polyethylene oxide -1500 35-40; glycerine 15-17; polyethylene oxide-400 and other components to 100.

EFFECT: ointment is characterised by antiseptic, anti-inflammatory and wound healing action.

9 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to pharmaceutical formulation for local dermal application to induce cytokine biosynthesis, containing immunomodulator 2-methyl-1-(2-methylpropyl)- 1H-imidazo[4,5-c][1,5]naphtirydine-4-amin, fatty acid, hydrophobic aprotonic component, emulsifier, hydrophilic component and water.

EFFECT: high effective induction of cytokine biosynthesis.

7 cl, 18 tbl, 140 ex

Poplar-aspen oil // 2326685

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, mixed oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts, with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, as well as fat extract of plant raw with plant component ratio as follows, mass.: marsh tea 3, comfrey 3, blueash 2, silver fir 1, common burdock (root) 2, horseheal (root) 1, deer's-tongue 1, horseradish 1, musquash-poison 2, hog bean (herb) 2, hop (cones) 2, cowberry (root) 2, mountain arnica (blossom) 2, ratio of oil extracts and fat extract of plant raw is 1:3 respectively.

EFFECT: agent allows widening range of preventive and therapeutic herbal medicinal agents of antiviral and anti-inflammatory action.

2 cl, 9 ex

Antiviral medicine // 2333751

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a suppository containing fullerene-polyhydropolyaminocaproic acid and auxiliary substances of dimethylsulfoxide, water-free lanolin or vegetable oil selected out of olive, peach, bumpkin seed oil, and base selected out of W-35 or H-15 vitepsol, cacao butter, solid fat, in the following amount per one 2 g suppository: fullerene-polyhydropolyaminocaproic acid 5-20 mg, diemthylsulfoxide 50-200 mg, water-free lanolin or vegetable oil 20-100 mg, the rest being the base.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

Up!